Skip to main content
. Author manuscript; available in PMC: 2020 Sep 2.
Published in final edited form as: J Neurooncol. 2020 Apr 27;148(2):231–244. doi: 10.1007/s11060-020-03517-5

Fig. 1. LB-100 and PD1 blockade elicit tumor rejection in murine glioblastoma.

Fig. 1

(a) C57BL/6 mice were inoculated with 1.3×105 GL261-Luc cells. When tumors reached 1.3 to 2.4 million p/sec/mm2, mice were randomized and treated every 2 days until survival endpoint or tumor regression. (b) BLI on the day of randomization, day 0, and after one cycle of treatment, day 2. (c) Cumulative survival of mice over time. (d) Representative BLI images of mice treated with each therapy over time. (e) C57BL/6 mice were similarly inoculated with GL261-WT cells. Mice were randomized on post-operative day 8. (f) Cumulative survival of mice with GL261-WT tumor over time. Survival experiment with GL261-Luc were performed in duplicate with ≥ 4 mice per arm. The combined data was presented. Survival experiment with GL261-WT were performed in duplicate with 8 mice per arm. The combined data was presented. **P<0.01, ***P<0.001 (log-rank test)